Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma

European Urology

Volumn 65, Issue 5, 2014, Pages 1014-1015

  Sun, Maxine ^a   Trinh, Quoc Dien ^b   Perrotte, Paul ^a   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PAZOPANIB; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MEDICATION COMPLIANCE; NOTE; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; FEMALE; KIDNEY TUMOR; MALE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 84896339985     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.12.042     Document Type: Note

References (3)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
2. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
3. P. Wolter, B. Beuselinck, S. Pans, and P. Schöffski Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors Acta Oncol 48 2009 621 624.